rs2911463 — PIEZO1

PIEZO1 and Varicose Veins — When Your Veins Cannot Feel the Flow

Every heartbeat sends a pulse of shear force across your endothelial cells — the single-cell lining that separates your blood from the vessel wall. Healthy endothelium translates this mechanical signal into a cascade of responses: nitric oxide release, cell alignment, vascular tone adjustment, and the structural remodeling that keeps veins from dilating under hydrostatic pressure. The molecule that detects the shear force and initiates this response is PIEZO1 — a mechanosensitive ion channel with 36 transmembrane domains that opens in response to membrane stretch and shear stress, allowing calcium influx that triggers downstream signaling¹¹ PIEZO1 — a mechanosensitive ion channel with 36 transmembrane domains that opens in response to membrane stretch and shear stress, allowing calcium influx that triggers downstream signaling.

rs2911463 is an intronic variant in the PIEZO1 gene on chromosome 16q24.3. The G allele at this locus is associated with elevated varicose vein risk in multiple large independent GWAS cohorts encompassing over 800,000 individuals. The association has been confirmed in UK Biobank, the 23andMe research cohort, and VA Million Veteran cohorts, reaching p-values as strong as 2×10⁻³⁴.

Varicose veins affect approximately 25% of women and 15% of men in Western populations. They are not merely cosmetic — tortuous, dilated superficial veins reflect underlying venous valve incompetence and sustained venous hypertension that, without intervention, can progress to chronic venous insufficiency, venous ulceration, and superficial thrombophlebitis.

The Mechanism

PIEZO1 is the primary endothelial mechanosensor in blood vessels. When the channel opens in response to shear stress or membrane tension, it allows calcium influx that activates calpain proteases, which reorganize the endothelial cytoskeleton so that cells align with blood flow direction. This flow-alignment response is fundamental to normal vascular development. Global or endothelial-specific deletion of Piezo1 in mice produces lethal vascular mis-patterning, with vessels failing to organize into appropriate arterial and venous networks²² Global or endothelial-specific deletion of Piezo1 in mice produces lethal vascular mis-patterning, with vessels failing to organize into appropriate arterial and venous networks
Li et al. 2014 demonstrated embryonic lethality and haploinsufficiency-driven endothelial defects in mature vessels.

In the venous system, sustained hydrostatic pressure (from prolonged standing or sitting) is a major mechanical stress on endothelial cells. Veins rely on PIEZO1-mediated mechanosensing to detect and compensate for this pressure by adjusting vascular tone and structural remodeling. Variants that alter PIEZO1 expression or activity in venous endothelium may impair this compensatory response, leaving the venous wall more vulnerable to progressive dilation, valve leaflet stress, and eventual incompetence.

rs2911463 is an intronic variant with no direct protein change; it likely acts as an expression quantitative trait locus (eQTL) in venous endothelial or smooth muscle cells, or tags a causal variant in regulatory elements within the PIEZO1 locus. The exact functional mechanism has not been characterized at the molecular level — the GWAS association is robust, but it awaits fine-mapping and functional validation in venous endothelial cell models.

PIEZO1 gain-of-function variants are separately known to cause dehydrated hereditary stomatocytosis (xerocytosis)³³ dehydrated hereditary stomatocytosis (xerocytosis)
a red blood cell disorder characterized by abnormal ion permeability causing cell dehydration, hemolytic anemia, and thromboembolic risk; autosomal dominant. The common GWAS variant rs2911463 is distinct from these rare pathogenic mutations — it is a common population variant with small effect size rather than a rare gain-of-function allele.

The Evidence

The PIEZO1 varicose vein association has been replicated across three major independent cohorts. Shadrina et al. 2019 in PLoS Genetics⁴⁴ Shadrina et al. 2019 in PLoS Genetics
GWAS of 408,455 European ancestry individuals; PIEZO1 prioritized as causal gene at one of 12 genome-wide significant loci; beta −0.0047, p=2×10⁻³⁴, the strongest single-locus signal in that study identified PIEZO1 among the most significant hits. Fukaya et al. 2018 in Circulation⁵⁵ Fukaya et al. 2018 in Circulation
UK Biobank analysis, 493,519 individuals, 9,577 varicose vein cases; 30 new loci identified; PIEZO1 among prioritized causal genes for loci overlapping mechanosensory and vascular development pathways independently confirmed PIEZO1's role. The Ahmed et al. 2022 Nature Communications paper⁶⁶ Ahmed et al. 2022 Nature Communications paper
135,514 cases and 675,111 controls combining UK Biobank and 23andMe cohorts; 49 genome-wide significant signals across 46 loci; enriched pathways include ECM biology, angiogenesis, vascular smooth muscle migration, and mechanosensation is the largest varicose vein genetic study to date, further substantiating the PIEZO1 locus.

The per-allele effect is modest (beta approximately 0.18 log-odds units in Fukaya 2018; similar in Shadrina). For GG homozygotes the cumulative effect is approximately equivalent to an OR of 1.3–1.4 compared to AA homozygotes when estimated from the additive model across studies. This is clinically meaningful for a condition with a 15–25% lifetime prevalence — even a 30–40% relative risk increase translates to substantial absolute risk in susceptible individuals.

Practical Actions

The PIEZO1 mechanism is directly relevant to exercise and physical activity patterns. PIEZO1-mediated mechanosensing is stimulated by blood flow shear stress — activities that increase venous return and intermittent hemodynamic loading (walking, calf raises, swimming) activate the PIEZO1 channel and support endothelial adaptation. Conversely, prolonged static loading (sustained standing or sitting without movement) is a major environmental trigger for varicose vein progression in genetically susceptible individuals.

Graduated compression garments act mechanically to reduce venous diameter and increase blood flow velocity — directly counteracting the hemodynamic stasis that impairs PIEZO1-mediated venous adaptation. Pharmacological interventions targeting venous tone (micronized purified flavonoid fractions, MPFF) have RCT evidence for chronic venous disease symptom reduction.

PIEZO1 is an actively investigated drug target. Small-molecule PIEZO1 activators (Yoda1 and its analogs) are in preclinical development for vascular and hematological applications. While no approved pharmacological PIEZO1 modulator exists for venous disease, this is a druggable target with an emerging pharmacological pipeline.

Interactions

PIEZO1 is one of several varicose vein GWAS loci with convergent vascular function. The VEGFA locus (rs11967262) is a co-identified hit in the same GWAS cohorts — VEGFA drives vascular permeability through endothelial junction regulation, a process that intersects with PIEZO1-mediated mechanotransduction in the endothelial response to hemodynamic stress. Carriers of risk alleles at both PIEZO1 and VEGFA carry additive polygenic risk for varicose vein development.

PIEZO1 variants also show pleiotropic effects on blood and vascular traits. The E756del gain-of-function variant (population-level in African ancestry) suppresses hepcidin through macrophage mechanotransduction pathways, affecting systemic iron levels. The GWAS variant rs2911463 is distinct and acts primarily in endothelial mechanosensation. PIEZO1 GWAS signals also overlap with red blood cell indices (reticulocyte count, MCHC) — suggesting that even common intronic variants modulate PIEZO1 expression in multiple tissues.